Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DuraDerm refers to two distinct medical products: a microbicidal liquid polymer and a cadaveric dermal allograft. The modern DuraDerm (often stylized as DuraDerm®) is an FDA-cleared 510(k) medical device consisting of an organic polymer dissolved in a methylene chloride solvent. Upon topical application, the solvent evaporates to form a clear, flexible, and occlusive elastomeric film that protects wounds from water, dirt, and pathogens while providing immediate microbicidal activity against bacteria, fungi, and viruses. It is indicated for minor wounds, scrapes, and post-operative care, and has been investigated for the reduction of pin track infections in orthopedic surgery. Historically, DuraDerm also referred to a decellularized cadaveric dermal allograft (Bard DuraDerm) used in reconstructive surgeries such as pubovaginal slings, though this product is largely discontinued.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DuraDerm.